{"nctId":"NCT00180687","briefTitle":"Clinical Trial of the Use of Intraperitoneal Local Anaesthetic","startDateStruct":{"date":"2004-10"},"conditions":["Pain, Postoperative"],"count":80,"armGroups":[{"label":"Control","type":"SHAM_COMPARATOR","interventionNames":["Other: No Intraperitoneal Therapeutics"]},{"label":"IP Aerosolized Normal Saline","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Normal Saline"]},{"label":"Nebulised Bupivacaine intraperitoneally","type":"EXPERIMENTAL","interventionNames":["Drug: Nebulised Bupivacaine intraperitoneally"]},{"label":"Injected Bupivacaine intraperitoneally","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Injected Bupivacaine intraperitoneally"]}],"interventions":[{"name":"Nebulised Bupivacaine intraperitoneally","otherNames":["Marcaine"]},{"name":"Normal Saline","otherNames":["0.9 % Normal Saline"]},{"name":"Injected Bupivacaine intraperitoneally","otherNames":["Marcaine"]},{"name":"No Intraperitoneal Therapeutics","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* All they patients undergoing laparoscopic cholecystectomy will be included.\n\nExclusion Criteria:\n\n* Patients with local anaesthetic allergy, patients on chronic opiate medication or those with neurological diseases that make pain evaluation unreliable will be excluded.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Reduction in Postoperative Pain","description":"Postoperative pain was measured using Pain scale 0-10 (0 = No Pain, 10 = Maximum pain). A trained nursing staff will ask the patient about his / her pain and document that correctly in the chart. The staff will also document if the patient requires any analgesia, the type and the dose.","paramType":"MEAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.2","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"3.3","spread":null},{"groupId":"OG003","value":"9.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.2","spread":null},{"groupId":"OG001","value":"8.1","spread":null},{"groupId":"OG002","value":"0.7","spread":null},{"groupId":"OG003","value":"7.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.9","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"0.6","spread":null},{"groupId":"OG003","value":"6.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.1","spread":null},{"groupId":"OG001","value":"6.2","spread":null},{"groupId":"OG002","value":"0.5","spread":null},{"groupId":"OG003","value":"5.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Vomiting / Nausea Episodes","description":"Nausea and vomiting are known adverse effect of opioids usage. By reducing the use of opioids we can reduce or abolish these side effect which will enhance early patient recovery and discharge and reduce hospital cost. We will measure the number of episodes when the patient suffers from these side effect and correlate them with opioids use.","paramType":"MEAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.1","spread":null},{"groupId":"OG001","value":"7.1","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"6.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Hours Needed for Safe Mobilization","description":"Drowsiness and delayed mobilization are known adverse effect of opioids usage. By reducing the use of opioids we can reduce or abolish these side effect which will enhance early patient recovery and discharge and reduce hospital cost. We will measure how many hours will take the patient to mobilize freely and safely and correlate them with opioids use.","paramType":"MEAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":null},{"groupId":"OG001","value":"6.5","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"6.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Postoperative Morphine Use","description":"The reduction in cost comes from reducing the use of opioid which requires nursing supervision and also special pump to be delivered as in the cases of patient controlled analgesia. With that reduction, there will be a reduction in opioid related adverse events that mandate medical or nursing attention and prolong hospitalization, these adverse events include nausea and vomiting, delay mobilization due to drowsiness and alter mental status caused by opioid usage. For these reasons we are collecting data related to these adverse events","paramType":"MEAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.9","spread":null},{"groupId":"OG001","value":"26.3","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"16.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":20},"commonTop":["Nausea and Vomiting"]}}}